Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region

GSK3389404, an N-acetyl galactosamine-conjugated antisense oligonucleotide (ASO), was in clinical development for chronic hepatitis B (CHB) treatment. Few studies have examined ASOs in Asian participants. In this analysis, the plasma pharmacokinetics (PK) of GSK3389404 were characterized and compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Kelong, Ito, Hiroshi, Elston, Robert, Cremer, Jennifer, Hood, Steve, Paff, Melanie, Theodore, Dickens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872700/
https://www.ncbi.nlm.nih.gov/pubmed/36507675
http://dx.doi.org/10.1128/aac.00900-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872700/
https://www.ncbi.nlm.nih.gov/pubmed/36507675
http://dx.doi.org/10.1128/aac.00900-22

Ejemplares similares